Novel molecular imaging platform for monitoring oncological kinases

Cancer Cell International

Volumn 10, Issue , 2010, Pages

  Nyati, Shyam ^a   Ross, Brian D ^a,b   Rehemtulla, Alnawaz ^a,b   Bhojani, Mahaveer S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIREFLY LUCIFERASE; PERIFOSINE; PROTEIN KINASE; PROTEIN KINASE B; PROTEINASE;

BIOLUMINESCENCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; MOLECULAR IMAGING; NONHUMAN; PHARMACODYNAMICS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 77955384924     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-10-23     Document Type: Review

References (88)

1. Sara H, Kallioniemi O, Nees M. A decade of cancer gene profiling: from molecular portraits to molecular function. Methods in molecular biology (Clifton, NJ) 576:61-87.
2. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008, 26(34):5630-5637. 10.1200/JCO.2008.17.3567, 18936473.
3. van de Rijn M, Gilks CB. Applications of microarrays to histopathology. Histopathology 2004, 44(2):97-108. 10.1111/j.1365-2559.2004.01766.x, 14764053.
4. Virtanen C, Woodgett J. Clinical uses of microarrays in cancer research. Methods in molecular medicine 2008, 141:87-113. full_text, 18453086.
5. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 2007, 7(7):545-553. 10.1038/nrc2173, 17585334.
6. Gazdar AF. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev 2010, 29(1):37-48. 10.1007/s10555-010-9201-z, 20127143.
7. Baselga J. The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer 2001, 37(Suppl 4):S16-22. 10.1016/S0959-8049(01)00233-7, 11597400.
8. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003, 95(12):851-867.
9. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005, 97(12):880-887.
10. Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol 2005, 16(4):538-548. 10.1093/annonc/mdi129, 15746148.
11. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, NY) 2004, 304(5676):1497-1500.
12. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14(4):320-368. 10.1634/theoncologist.2008-0230, 19346299.
13. Weissleder R, D RB, Rehemtulla A, Gambhir SS. Molecular Imaging, Principles and Practice. Shelton, Connecticut, USA: People's Medical Publishing House-USA 2010,
14. Bhojani MS, Ross BD, Rehemtulla A. Imaging of signaling pathways. Molecular Imaging, Priniciples and Practice 2010, 829-841. People's Medical Publishing House-USA, Shelton, CT, USA, Weissleder R, D RB, Rehemtulla A, Gambhir SS.
15. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nature medicine 2003, 9(1):123-128. 10.1038/nm0103-123, 12514725.
16. Mahmood U, Weissleder R. Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther 2003, 2(5):489-496.
17. Gelovani Tjuvajev J, Blasberg RG. In vivo imaging of molecular-genetic targets for cancer therapy. Cancer Cell 2003, 3(4):327-332. 10.1016/S1535-6108(03)00082-5, 12726859.
18. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000, 92(24):2029-2036. 10.1093/jnci/92.24.2029, 11121466.
19. Moffat BA, Hall DE, Stojanovska J, McConville PJ, Moody JB, Chenevert TL, Rehemtulla A, Ross BD. Diffusion imaging for evaluation of tumor therapies in preclinical animal models. Magma 2004, 17(3-6):249-259. 10.1007/s10334-004-0079-z, 15580371.
20. Guccione S, Li KC, Bednarski MD. Molecular imaging and therapy directed at the neovasculature in pathologies. How imaging can be incorporated into vascular-targeted delivery systems to generate active therapeutic agents. IEEE Eng Med Biol Mag 2004, 23(5):50-56. 10.1109/MEMB.2004.1360408, 15565799.
21. Morgan B, Horsfield MA, Steward WP. The role of imaging in the clinical development of antiangiogenic agents. Hematol Oncol Clin North Am 2004, 18(5):1183-1206. x, 10.1016/j.hoc.2004.06.011, 15474341.
22. Contag CH, Bachmann MH. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 2002, 4:235-260. 10.1146/annurev.bioeng.4.111901.093336, 12117758.
23. Bremer C, Ntziachristos V, Weissleder R. Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol 2003, 13(2):231-243.
24. Bhaumik S, Gambhir SS. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(1):377-382. 10.1073/pnas.012611099, 117568, 11752410.
25. Ross BD, Chenevert TL, Rehemtulla A. Magnetic resonance imaging in cancer research. Eur J Cancer 2002, 38(16):2147-2156. 10.1016/S0959-8049(02)00387-8, 12387840.
26. Blasberg R. PET imaging of gene expression. Eur J Cancer 2002, 38(16):2137-2146. 10.1016/S0959-8049(02)00390-8, 12387839.
27. Blasberg RG, Gelovani J. Molecular-genetic imaging: a nuclear medicine-based perspective. Mol Imaging 2002, 1(3):280-300. 10.1162/153535002760235472, 12920854.
28. Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H. PET: a revolution in medical imaging. Radiol Clin North Am 2004, 42(6):983-1001. vii, 10.1016/j.rcl.2004.08.012, 15488553.
29. Bhojani MS, Laxman B, Ross BD, Rehemtulla A. Molecular Imaging in Cancer. Apoptosis and Cancer Therapy 2006, II:37-59. Weinheim: Wiley-VCH, DKMaF S.
30. Zhang L, Bhojani MS, Ross BD, Rehemtulla A. Molecular imaging of protein kinases. Cell cycle (Georgetown, Tex) 2008, 7(3):314-317.
31. Gross S, Piwnica-Worms D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 2005, 7(1):5-15.
32. Narula J, Kietselaer B, Hofstra L. Role of molecular imaging in defining and denying death. J Nucl Cardiol 2004, 11(3):349-357. 10.1016/j.nuclcard.2004.03.008, 15173781.
33. Greer LF, Szalay AA. Imaging of light emission from the expression of luciferases in living cells and organisms: a review. Luminescence 2002, 17(1):43-74. 10.1002/bio.676, 11816060.
34. Contag CH, Ross BD. It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging 2002, 16(4):378-387. 10.1002/jmri.10178, 12353253.
35. Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, Contag CH, Ross BD. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia (New York, NY) 2000, 2(6):491-495.
36. Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I, Parker MG, Lowik C, Maggi A. In vivo imaging of transcriptionally active estrogen receptors. Nature medicine 2003, 9(1):82-86. 10.1038/nm809, 12483206.
37. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-kappa B activity. J Immunol 2002, 168(3):1441-1446.
38. Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, Humm J, Larson S, Sadelain M, Blasberg R, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(16):9300-9305. 10.1073/pnas.161091198, 55415, 11481488.
39. Rehemtulla A, Taneja N, Ross BD. Bioluminescence detection of cells having stabilized p53 in response to a genotoxic event. Mol Imaging 2004, 3(1):63-68. 10.1162/153535004773861732, 15142413.
40. Laxman B, Hall DE, Bhojani MS, Hamstra DA, Chenevert TL, Ross BD, Rehemtulla A. Noninvasive real-time imaging of apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(26):16551-16555. 10.1073/pnas.252644499, 139181, 12475931.
41. Luker GD, Sharma V, Pica CM, Prior JL, Li W, Piwnica-Worms D. Molecular imaging of protein-protein interactions: controlled expression of p53 and large T-antigen fusion proteins in vivo. Cancer research 2003, 63(8):1780-1788.
42. Papadakis ED, Nicklin SA, Baker AH, White SJ. Promoters and control elements: Designing expression cassettes for gene therapy. Current Gene Therapy 2004, 4(1):89-113. 10.2174/1566523044578077, 15032617.
43. Ray P, De A, Min JJ, Tsien RY, Gambhir SS. Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer research 2004, 64(4):1323-1330. 10.1158/0008-5472.CAN-03-1816, 14973078.
44. Sadeghi H, Hitt MA. Transcriptionally targeted adenovirus vectors. Current Gene Therapy 2005, 5(4):411-427. 10.2174/1566523054546189, 16101515.
45. Jaffer FA, Tung CH, Gerszten RE, Weissleder R. In vivo Imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe. Arteriosclerosis Thrombosis and Vascular Biology 2002, 22(11):1929-1935.
46. Livet J, Weissman TA, Kang HN, Draft RW, Lu J, Bennis RA, Sanes JR, Lichtman JW. Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature 2007, 450(7166):56. 10.1038/nature06293, 17972876.
47. Fields S, Song O. A novel genetic system to detect protein-protein interactions. Nature 1989, 340(6230):245-246. 10.1038/340245a0, 2547163.
48. Hu CD, Chinenov Y, Kerppola TK. Visualization of interactions among bZIP and Rel family proteins in living cells using bimolecular fluorescence complementation. Mol Cell 2002, 9(4):789-798. 10.1016/S1097-2765(02)00496-3, 11983170.
49. Luker GD, Sharma V, Pica CM, Dahlheimer JL, Li W, Ochesky J, Ryan CE, Piwnica-Worms H, Piwnica-Worms D. Noninvasive imaging of protein-protein interactions in living animals. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(10):6961-6966. 10.1073/pnas.092022399, 124511, 11997447.
50. Luker KE, Piwnica-Worms D. Optimizing luciferase protein fragment complementation for bioluminescent imaging of protein-protein interactions in live cells and animals. Methods in enzymology 2004, 385:349-360. full_text, 15130748.
51. Galarneau A, Primeau M, Trudeau LE, Michnick SW. Beta-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein protein interactions. Nature biotechnology 2002, 20(6):619-622. 10.1038/nbt0602-619, 12042868.
52. Michnick SW, Ear PH, Manderson EN, Remy I, Stefan E. Universal strategies in research and drug discovery based on protein-fragment complementation assays. Nature reviews 2007, 6(7):569-582. 10.1038/nrd2311, 17599086.
53. Remy I, Michnick SW. A highly sensitive protein-protein interaction assay based on Gaussia luciferase. Nat Methods 2006, 3(12):977-979. 10.1038/nmeth979, 17099704.
54. Remy I, Michnick SW. Application of protein-fragment complementation assays in cell biology. Biotechniques 2007, 42(2):137. 139, 141 passim, 10.2144/000112396, 17373475.
55. Paulmurugan R, Gambhir SS. Monitoring protein-protein interactions using split synthetic renilla luciferase protein-fragment-assisted complementation. Anal Chem 2003, 75(7):1584-1589. 10.1021/ac020731c, 12705589.
56. Li WR, Li F, Huang Q, Frederick B, Bao SD, Li CY. Noninvasive imaging and quantification of epidermal growth factor receptor kinase activation in vivo. Cancer research 2008, 68(13):4990-4997. 10.1158/0008-5472.CAN-07-5984, 18593895.
57. Zhang L, Lee KC, Bhojani MS, Khan AP, Shilman A, Holland EC, Ross BD, Rehemtulla A. Molecular imaging of Akt kinase activity. Nature medicine 2007, 13(9):1114-1119. 10.1038/nm1608, 17694068.
58. Zhang L, Bhojani MS, Ross BD, Rehemtulla A. Enhancing Akt imaging through targeted reporter expression. Mol Imaging 2008, 7(4):168-174. 2659640, 19123987.
59. Coppola JM, Ross BD, Rehemtulla A. Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin Cancer Res 2008, 14(8):2492-2501. 10.1158/1078-0432.CCR-07-0782, 2668201, 18413842.
60. Manning G, Plowman GD, Hunter T, Sudarsanam S. Evolution of protein kinase signaling from yeast to man. Trends in biochemical sciences 2002, 27(10):514-520. 10.1016/S0968-0004(02)02179-5, 12368087.
61. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science (New York, NY) 2002, 298(5600):1912-1934.
62. Edelman AM, Blumenthal DK, Krebs EG. Protein serine/threonine kinases. Annual review of biochemistry 1987, 56:567-613.
63. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annual review of biochemistry 2000, 69:373-398. 10.1146/annurev.biochem.69.1.373, 10966463.
64. Hunter T, Cooper JA. Protein-tyrosine kinases. Annual review of biochemistry 1985, 54:897-930.
65. Tsygankov AY. Non-receptor protein tyrosine kinases. Front Biosci 2003, 8:s595-635. 10.2741/1106, 12700079.
66. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001, 411(6835):355-365. 10.1038/35077225, 11357143.
67. Ben-Bassat H. Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy. Curr Opin Investig Drugs 2001, 2(11):1539-1545.
68. Blease K. Targeting kinases in asthma. Expert opinion on investigational drugs 2005, 14(10):1213-1220. 10.1517/13543784.14.10.1213, 16185163.
69. Kumar R, Singh VP, Baker KM. Kinase inhibitors for cardiovascular disease. J Mol Cell Cardiol 2007, 42(1):1-11. 10.1016/j.yjmcc.2006.09.005, 17059822.
70. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nature reviews 2005, 4(5):387-398. 10.1038/nrd1719, 15864268.
71. Westra J, Limburg PC. p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis. Mini Rev Med Chem 2006, 6(8):867-874. 10.2174/138955706777934982, 16918493.
72. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007, 129(7):1261-1274. 10.1016/j.cell.2007.06.009, 2756685, 17604717.
73. Bailey HH, Mahoney MR, Ettinger DS, Maples WJ, Fracasso PM, Traynor AM, Erlichman C, Okuno SH. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer 2006, 107(10):2462-2467. 10.1002/cncr.22308, 17058289.
74. Vink SR, Schellens JH, Beijnen JH, Sindermann H, Engel J, Dubbelman R, Moppi G, Hillebrand MJ, Bartelink H, Verheij M. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol 2006, 80(2):207-213. 10.1016/j.radonc.2006.07.032, 16914220.
75. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annual review of biochemistry 1999, 68:965-1014. 10.1146/annurev.biochem.68.1.965, 10872470.
76. Cantley LC. The phosphoinositide 3-kinase pathway. Science (New York, NY) 2002, 296(5573):1655-1657.
77. Nyati S, Ranga R, Ross BD, Rehemtulla A, MS B. Molecular Imaging of GSK3β and CK1α kinases. Analytical Biochemistry 2010,
78. Cohen P, Knebel A. KESTREL: a powerful method for identifying the physiological substrates of protein kinases. The Biochemical journal 2006, 393(Pt 1):1-6. 1383659, 16336195.
79. Murray JT, Campbell DG, Peggie M, Mora A, Cohen P. Identification of filamin C as a new physiological substrate of PKBalpha using KESTREL. The Biochemical journal 2004, 384(Pt 3):489-494. 1134134, 15461588.
80. Peng C, Knebel A, Morrice NA, Li X, Barringer K, Li J, Jakes S, Werneburg B, Wang L. Pim kinase substrate identification and specificity. Journal of biochemistry 2007, 141(3):353-362. 10.1093/jb/mvm040, 17234686.
81. Huang HD, Lee TY, Tzeng SW, Horng JT. KinasePhos: a web tool for identifying protein kinase-specific phosphorylation sites. Nucleic acids research 2005, (33 Web Server):W226-229. 10.1093/nar/gki471, 1160232, 15980458.
82. Senawongse P, Dalby AR, Yang ZR. Predicting the phosphorylation sites using hidden Markov models and machine learning methods. Journal of chemical information and modeling 2005, 45(4):1147-1152. 10.1021/ci050047+, 16045309.
83. Wong YH, Lee TY, Liang HK, Huang CM, Wang TY, Yang YH, Chu CH, Huang HD, Ko MT, Hwang JK. KinasePhos 2.0: a web server for identifying protein kinase-specific phosphorylation sites based on sequences and coupling patterns. Nucleic acids research 2007, (35 Web Server):W588-594. 10.1093/nar/gkm322, 1933228, 17517770.
84. Niedner RH, Buzko OV, Haste NM, Taylor A, Gribskov M, Taylor SS. Protein kinase resource: an integrated environment for phosphorylation research. Proteins 2006, 63(1):78-86. 10.1002/prot.20825, 16435372.
85. Petretti C, Prigent C. The Protein Kinase Resource: everything you always wanted to know about protein kinases but were afraid to ask. Biology of the cell/under the auspices of the European Cell Biology Organization 2005, 97(2):113-118.
86. Smith CM. The protein kinase resource and other bioinformation resources. Progress in biophysics and molecular biology 1999, 71(3-4):525-533. 10.1016/S0079-6107(98)00046-7, 10354712.
87. Smith CM, Shindyalov IN, Veretnik S, Gribskov M, Taylor SS, Ten Eyck LF, Bourne PE. The protein kinase resource. Trends in biochemical sciences 1997, 22(11):444-446. 10.1016/S0968-0004(97)01131-6, 9397688.
88. MacDonald JA, Mackey AJ, Pearson WR, Haystead TA. A strategy for the rapid identification of phosphorylation sites in the phosphoproteome. Mol Cell Proteomics 2002, 1(4):314-322. 10.1074/mcp.M200002-MCP200, 12096113.